Moving from 2.5mg to 5mg Mounjaro: what actually changes

The biggest misconception: that 2.5mg is meant to work on its own

Many people starting Mounjaro expect the first pen to produce visible results. When it doesn't, they worry something is wrong. In fact, 2.5mg is not a weight-loss dose. It is a four-week settling period designed to reduce the nausea, indigestion and stomach-adjustment symptoms that can come with a new GLP-1 or dual-agonist medicine. The NHS tirzepatide guidance is clear: treatment begins at 2.5mg for tolerability, with dose increases following from there.

So if the first pen brought only modest appetite changes and no dramatic shift on the scales, that is exactly what was supposed to happen. The 5mg pen is where the pharmacological effect of tirzepatide (acting on both GIP and GLP-1 receptors to reduce appetite and slow gastric emptying) starts working at a meaningful level. Knowing that changes how most people feel about the step up. It is not an escalation because 2.5mg failed. It is the treatment beginning.

If you have questions about what the 2.5mg starter period involves in practice, that detail is covered separately.

What the step from 2.5mg to 5mg involves, and what your body may notice

The increase to 5mg happens after approximately four weeks on the starter dose, assuming your prescriber is satisfied you have tolerated it well. You continue using the same once-weekly injection routine; the only thing changing is the dose delivered by the pen. For details on the pen itself, the 2.5mg KwikPen page covers the device in full, the 5mg pen works the same way.

Appetite suppression tends to become more noticeable after the step up. Some people also notice a return of mild nausea or digestive changes in the first week or two at the new strength. This is normal and generally settles. The pattern (a brief adjustment period each time the dose increases) is consistent throughout the titration schedule. Staying well-hydrated, eating smaller portions and avoiding high-fat meals in the hours around your injection are the practical steps most prescribers suggest.

The side-effect profile at 5mg is similar in character to 2.5mg: nausea, constipation, loose stools, reflux and fatigue are the most commonly reported, with GI effects most pronounced early on. They are not a sign that you need to stop; they are a sign the medicine is active. That said, severe or persistent stomach pain (especially pain spreading to the back) should prompt same-day medical attention, as the MHRA highlighted in its Drug Safety Update guidance on GLP-1 medicines and pancreatitis.

If, at any point, 5mg proves difficult to tolerate, stepping back is an option your prescriber can discuss. The question of reducing back to 2.5mg is one prescribers encounter regularly, it is not unusual.

How prescribers decide the increase is ready to happen

No dose increase at nume happens on a timer alone. Before each step up, a clinician (a real GPhC-registered Independent Prescriber, not an automated system) reviews your progress, any side effects you have reported, and whether 5mg is clinically appropriate for you at this point. That review is the same-day process that applies to every stage of treatment, not just the initial approval.

Patients transferring from another service, or requesting a dose increase, are asked to provide evidence of their current treatment stage. This is a safety measure, not a bureaucratic one: it means no one is pushed to a higher dose before their body is ready, and it reflects the approach set out in NICE's appraisal of tirzepatide (TA1026), which recommends clinical oversight throughout treatment.

The broader Mounjaro treatment overview sets out the full licensed dose schedule and what ongoing clinical review looks like. For those who want to understand the specific 5mg strength in more depth, the 5mg dose page covers the evidence and expectations at that level. And if you are weighing up how to begin treatment or are currently on a waiting list, our weight-loss treatment overview explains the private route and what it includes, including one price covering consultation, prescription and delivery, with no subscription and no hidden charges. The step-by-step guide to the 2.5mg-to-5mg transition gives a more granular look at the practical sequence.

When your pen does arrive (once clinically approved and dispatched) it comes via DPD tracked delivery, in plain unbranded packaging, with no indication of the contents on the outside. The pen is refrigerated on arrival; your patient information leaflet will confirm the exact room-temperature window if you ever need to transport it.